Should antiretroviral therapy be started earlier?

Joel E. Gallant

Research output: Contribution to journalArticle

Abstract

Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm 3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalCurrent HIV/AIDS Reports
Volume4
Issue number2
DOIs
StatePublished - May 2007

Fingerprint

CD4 Lymphocyte Count
Therapeutics
Poisons
Secondary Prevention
Guidelines
Costs and Cost Analysis

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Should antiretroviral therapy be started earlier? / Gallant, Joel E.

In: Current HIV/AIDS Reports, Vol. 4, No. 2, 05.2007, p. 53-59.

Research output: Contribution to journalArticle

Gallant, Joel E. / Should antiretroviral therapy be started earlier?. In: Current HIV/AIDS Reports. 2007 ; Vol. 4, No. 2. pp. 53-59.
@article{f0e7800906284ea7bcb0372e9e3cfffb,
title = "Should antiretroviral therapy be started earlier?",
abstract = "Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm 3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.",
author = "Gallant, {Joel E.}",
year = "2007",
month = "5",
doi = "10.1007/s11904-007-0008-7",
language = "English (US)",
volume = "4",
pages = "53--59",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Should antiretroviral therapy be started earlier?

AU - Gallant, Joel E.

PY - 2007/5

Y1 - 2007/5

N2 - Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm 3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.

AB - Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm 3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=34249314052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249314052&partnerID=8YFLogxK

U2 - 10.1007/s11904-007-0008-7

DO - 10.1007/s11904-007-0008-7

M3 - Article

C2 - 17547825

AN - SCOPUS:34249314052

VL - 4

SP - 53

EP - 59

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 2

ER -